The CRL is a complete turnaround from the positive recommendation Onpattro received in September from an FDA Advisory Committee (AdCom) panel regarding the label expansion. Image Credit: file404/Shutterstock.

Alnylam Pharmaceuticals has had to abandon its plans to pursue a label expansion of Onpattro (patisiran) after the US Food and Drug Administration (FDA) issued a complete response letter (CRL).

The CRL was issued regarding the New Drug Application (sNDA) for Onpattro for the treatment of the cardiomyopathy of transthyretin mediated (ATTR) amyloidosis. The letter cited that there was insufficient evidence to demonstrate Onpattro’s clinical efficacy in treating cardiomyopathy caused by the wild-type or hereditary ATTR amyloidosis, therefore, the drug “could not be approved in its present form”.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Alnylam was quick to add that the CRL did not identify any issues with the clinical trial or drug quality and manufacturing.

The CRL is a complete turnaround from the positive recommendation Onpattro received from an FDA Advisory Committee (AdCom) panel in September regarding the label expansion. The panel voted nine to three in favour of approving the therapy for the cardiomyopathy condition.

Onpattro is an RNA interference (RNAi) therapy that was first approved by the FDA for the treatment of hereditary ATTR amyloidosis polyneuropathy in 2018. Onpattro reduces the amount of mutant or wild-type transthyretin (TTR), a transport protein present in the liver, by silencing the mutant TTR mRNA in hereditary ATTR amyloidosis.

ATTR amyloidosis is a rare condition caused by the build-up of TTR, characterised by clumps in the body’s organs and peripheral nerves. In the case of polyneuropathy, TTR build-up takes place in the peripheral nerves, thereby causing symptoms like tingling, numbness, or pain in the hands and feet, whereas in the case of cardiomyopathy, these TTR clumps are deposited in the cardiac tissue leading to heart failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the CRL, the company stated that it will “no longer pursue an expanded indication for Onpattro in the US”.

Alnylam is also investigating another RNAi therapy, vutrisiran, for treating cardiomyopathy of ATTR amyloidosis in a Phase III trial (NCT04153149). The top-line results from the trial are expected in early 2024.

Onpattro’s sNDA application was supported by data from the placebo-controlled Phase III trial (NCT03997383). The study met its primary endpoint by showing a significant difference in functional capacity, as measured using the 6-Minute Walk Test (6-MWT), compared with the placebo.

In July, Roche licensed Alnylam’s hypertension RNAi therapy, zilebesiran, for an upfront payment of $310m (SFr281.99m). The latter is also entitled to milestone and royalty payments for this deal. Both companies will share the marketing costs and profits from the drug in the US, whilst Roche will be solely responsible for these outside the US.